J Clin Invest. 2014 Jun;124(6):2333-40. doi: 10.1172/JCI72271. Epub 2014 Jun 2.
Diabetic kidney disease (DKD) is the leading cause of kidney failure worldwide and the single strongest predictor of mortality in patients with diabetes. DKD is a prototypical disease of gene and environmental interactions. Tight glucose control significantly decreases DKD incidence, indicating that hyperglycemia-induced metabolic alterations, including changes in energy utilization and mitochondrial dysfunction, play critical roles in disease initiation. Blood pressure control, especially with medications that inhibit the angiotensin system, is the only effective way to slow disease progression. While DKD is considered a microvascular complication of diabetes, growing evidence indicates that podocyte loss and epithelial dysfunction play important roles. Inflammation, cell hypertrophy, and dedifferentiation by the activation of classic pathways of regeneration further contribute to disease progression. Concerted clinical and basic research efforts will be needed to understand DKD pathogenesis and to identify novel drug targets.
糖尿病肾病(DKD)是全球范围内导致肾衰竭的主要原因,也是糖尿病患者死亡的单一最强预测因素。DKD 是基因与环境相互作用的典型疾病。严格控制血糖可显著降低 DKD 的发病率,表明高血糖引起的代谢改变,包括能量利用和线粒体功能障碍的改变,在疾病发生中起关键作用。血压控制,特别是使用抑制血管紧张素系统的药物,是减缓疾病进展的唯一有效方法。虽然 DKD 被认为是糖尿病的微血管并发症,但越来越多的证据表明,足细胞丢失和上皮功能障碍起着重要作用。通过经典的再生途径的激活导致的炎症、细胞肥大和去分化进一步促进疾病进展。需要协同的临床和基础研究努力来了解 DKD 的发病机制,并确定新的药物靶点。